Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Advanced Bifurcation Systems to Sponsor XIII European Bifurcation Club Meeting


Posted on: 18 Sep 17

LOS ANGELES, Sept. 18, 2017 (GLOBE NEWSWIRE) -- Advanced Bifurcation Systems (“ABS” or the “Company”), a clinical stage medical device company developing an innovative stenting platform which overcomes the limitations of current approaches for the treatment of bifurcation lesions in coronary angioplasties, today announced that the Company will be a sponsor of the XIII European Bifurcation Club (www.bifurc.net) meeting at the Casa Das Artes in Porto, Portugal on Friday, October 13th and Saturday, October 14th, 2017.  Dr. Mehran Khorsandi, the Company’s co-founder, chairman and chief medical officer will make a presentation entitled "Bifurcations Made Easy" at the conference.

“Our platform based technology is unlike anything on the market today.  We have put extensive patent protection in place and are working with key institutions and KOL’s to advance our program as we move forward to commercialize the technology and pursue regulatory approval,” commented CEO Charles Laverty.

Advanced Bifurcation Systems, through its novel Mother/Daughter (“MD”) platform, has complete coverage for all lesions regardless of branch angle, size, plaque burden or location.  This single system addresses both the main and side branch, and is mechanically fail-safe and self-aligning for perfect placement. 

Dr. Mehran Khorsandi commented, “We have really worked hard to perfect our technology and believe that when we commercialize our product more interventional cardiologists will be comfortable doing complex bifurcations.  Our unique technology enables assembly of a bifurcating stent at the carina, regardless of angles, sizes or plaque burden.  We expect that our platform, which has been tested in 10 patients to date, will require limited training, greatly reduce procedure times and improve clinical outcomes.”

About Advanced Birfurcation Systems

Advanced Bifurcation Systems (“ABS”) is a clinical stage medical device company developing an innovative stenting platform for simple treatment of all bifurcation lesions in coronary angioplasties. ABS has developed a novel technology which overcomes the limitations of current approaches while simplifying the procedure.  The Company’s groundbreaking system consists of numerous differentiating features, including a unique modular independently movable dual-catheter system for provisional side-branch stenting as well as full bifurcation stenting with a proprietary crimping technology allowing for partial crimping of the main stent.  For more information, go to www.advancedbifurcation.com.

About EBC 2017
The European Bifurcation Club is an organization of European thought leaders in the treatment of coronary bifurcation lesions.  The group holds an annual meeting to interact with the medical industry on the development of new concepts, processes and devices as well as to give scientific credibility to new clinical and technological projects.

Contact:

Advanced Birfurcation Systems
Charles Laverty
Chief Executive Officer
charles_laverty@advancedbifurcation.com
(949)432-4824

GlobeNewswire
globenewswire.com

Last updated on: 18/09/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.